Virtus ETF Advisers LLC Cyma Bay Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$12.63 - $24.47 $89,230 - $172,880	-7,065 Reduced 62.29%	4,278 $101,000
Q3 2023 Nov 07, 2023	SELL	$10.86 - $17.62 $12,239 - $19,857	-1,127 Reduced 9.04%	11,343 $169,000
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $93,150 - $136,546	12,470 New	12,470 $136,000
Q4 2019 Feb 13, 2020	SELL	$1.33 - $5.93 $53,508 - $238,575	-40,232 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$5.12 - $7.21 $11,473 - $16,157	-2,241 Reduced 5.28%	40,232 $206,000
Q2 2019 Aug 13, 2019	BUY	$6.05 - $13.66 $69,732 - $157,445	11,526 Added 37.24%	42,473 $304,000
Q1 2019 May 14, 2019	SELL	$8.16 - $13.42 $28,478 - $46,835	-3,490 Reduced 10.13%	30,947 $411,000
Q4 2018 Feb 05, 2019	SELL	$6.54 - $11.74 $11,006 - $19,758	-1,683 Reduced 4.66%	34,437 $271,000
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $281,041 - $375,066	-25,831 Reduced 41.7%	36,120 $400,000
Q2 2018 Aug 10, 2018	SELL	$10.66 - $14.38 $334,361 - $451,043	-31,366 Reduced 33.61%	61,951 $831,000
Q1 2018 May 14, 2018	BUY	$9.0 - $15.16 $457,488 - $770,613	50,832 Added 119.65%	93,317 $1.21 Million
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $325,859 - $395,535	42,485	42,485 $391,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.